A Phase III Study of Gemcitabine-Nab-Paclitaxel With or Without Daraxonrasib (RMC-6236) or Daraxonrasib Monotherapy in Untreated Metastatic Pancreatic Cancer

Full Title

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Wungki Park’s office at 646-888-4543.

Protocol
26-215
Phase
Phase III (phase 3)
Disease Status
Newly Diagnosed
Investigator
Wungki Park
Co-Investigators
Eileen M. O'Reilly
Diseases
Hepatobiliary › Pancreatic Cancer
Upper Gastrointestinal › Pancreatic Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07491445
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description